Sandoz Files Application For Biosimilar To Amgen's Enbrel

Law360, New York (October 2, 2015, 4:48 PM ET) -- The U.S. Food and Drug Administration has accepted Sandoz Inc.'s application for a proposed biosimilar to Amgen Inc.'s biologic arthritis drug Enbrel, the company announced on Friday, about a month after it launched its first biosimilar to an Amgen drug.



The Novartis AG subsidiary is seeking approval of the biosimilar for all uses included on Enbrel's label. The biosimilar is a tumor necrosis factor alpha inhibitor, also known as an anti-TNF — a drug that suppresses the body's response to cell death — and is used...

To view the full article, register now.